Zofran (Ondasetron): Difference between revisions

From Anesthesia Wiki
Jump to navigation Jump to search
No edit summary
No edit summary
Line 5: Line 5:
{{Infobox drug
{{Infobox drug
| Drug_name = Zofran
| Drug_name = Zofran
| IUPAC_name = (RS)-1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one
| Image = Zofran.png
| Image = Zofran.png
| Caption = Zofran 4 mg tablet
| Caption = Zofran 4 mg tablet
Line 18: Line 17:
| Elimination_half-life = 3-6 hours
| Elimination_half-life = 3-6 hours
| Excretion = Kidney (60%), feces (40%)
| Excretion = Kidney (60%), feces (40%)
| CAS_number = 99614-02-5
| PubChem = 43815
}}
}}



Revision as of 20:19, 16 May 2023


Zofran (Ondasetron)


Zofran (ondansetron) is an antiemetic medication used to prevent nausea and vomiting, particularly in the field of anesthesia. It is a selective 5-HT3 receptor antagonist, which works by blocking the action of serotonin in the brain and the gastrointestinal tract.

Route of administration

  • Oral: Disintegrating tablets, film-coated tablets, and oral solution
  • Intravenous: Injection
  • Intramuscular: Injection

Dose

For anesthesia-related nausea and vomiting:

  • Adult:
 * Oral: 16 mg before anesthesia induction
 * Intravenous: 4 mg before anesthesia induction or immediately before/during/after surgery
  • Pediatric:
 * Oral: 4 mg for children aged 4-11 years, 30-60 minutes before surgery
 * Intravenous: 0.1 mg/kg (up to 4 mg) for children aged 1 month-12 years, immediately before/during/after surgery

Half-life

  • The elimination half-life of ondansetron is approximately 3-6 hours.

Expected time to work

  • Oral: Onset of action is approximately 30 minutes to 2 hours.
  • Intravenous: Onset of action is approximately 5-30 minutes.

Use in anesthesia

Zofran is commonly used in anesthesia to:

  • Prevent postoperative nausea and vomiting (PONV)
  • Prevent nausea and vomiting induced by chemotherapy
  • Prevent nausea and vomiting associated with radiation therapy

Side effects

  • Headache
  • Fatigue
  • Constipation
  • Diarrhea
  • Dizziness

Contraindications

  • Hypersensitivity to ondansetron or any component of the formulation
  • Concomitant use with apomorphine
  • Patients with congenital long QT syndrome

Drug interactions

References


External links